Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.32 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.32 |
| ▸ | CTRC | Q99895 | 1/20 | 0.31 |
| ▸ | NOS3 | P29474 | 1/20 | 0.30 |
| ▸ | NOS1 | P29475 | 1/20 | 0.30 |
| ▸ | NOS2 | P35228 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12797849 | 0.81 | POLB (0.41) | POLBHTTGABRA1GABRB2CTRC | |
| SCHEMBL19972040 | 0.76 | PRKCI (0.32) | NOS2 | |
| SCHEMBL459601 | 0.74 | POLB (0.37) | POLBHTTGABRA1GABRB2CTRC | |
| SCHEMBL393531 | 0.72 | POLB (0.35) | POLBHTTGABRA1GABRB2CTRC | |
| SCHEMBL15751161 | 0.71 | GABRA1 (0.44) | POLBHTTGABRA1GABRB2 | |
| SCHEMBL11482002 | 0.71 | GABRA1 (0.44) | GABRA1GABRB2 | |
| SCHEMBL262868 | 0.70 | GABRA1 (0.55) | POLBHTTGABRA1GABRB2 | |
| SCHEMBL1332031 | 0.70 | GABRA1 (0.55) | POLBHTTGABRA1GABRB2 | |
| SCHEMBL5184430 | 0.70 | GABRA1 (0.55) | GABRA1GABRB2 | |
| SCHEMBL9505579 | 0.70 | GABRA1 (0.54) | POLBHTTGABRA1GABRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9957241-B2 | Aromatic diamine, an intermediate therefor, a method for producing the aromatic diamine, and a method for producing the intermediate therefor | SEIKA CORPORATION (JP) | 2018-05-01 | — | — | US | disclosed |
| US-20180079732-A1 | AROMATIC DIAMINE, AN INTERMEDIATE THEREFOR, A METHOD FOR PRODUCING THE AROMATIC DIAMINE, AND A METHOD FOR PRODUCING THE INTERMEDIATE THEREFOR | SEIKA CORPORATION (JP) | 2018-03-22 | — | — | US | disclosed |
| CN-107531652-A | Aromatic diamine, intermediate thereof, and processes for producing these | 精化株式会社 | 2018-01-02 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180079732-A1 | AROMATIC DIAMINE, AN INTERMEDIATE THEREFOR, A METHOD FOR PRODUCING THE AROMATIC DIAMINE, AND A METHOD FOR PRODUCING THE INTERMEDIATE THEREFOR | WEE1, WEE2, WASF2 | POLB 2855/4885HTT 3592/4885GABRA1 409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.